DRE’s Medical Strategy Advisory Board (MSAB) advises DRE on the convergence between expert AI-enabled technology in healthcare and the exponential growth of clinical information. DRE is dedicated to applying sophisticated data science with advanced AI to generate quicker, deeper, more nuanced regulatory-grade scientific and clinical insights for the betterment of patient outcomes and the MSAB is a steering committee governance Board to ensure that our mission is achieved.

Ameet Nathwani MD, MRCP, DipPharmMed, MBA

Chairman, Medical Strategic Advisory Board

With more than 25 years of experience in the pharmaceutical industry, Dr. Nathwani was most recently an Executive Committee member at Sanofi AG, as Chief Medical Officer, Head of Medical and Chief Digital Officer, responsible for enhancing Sanofi’s strategy to integrate digital technologies and medical science to ultimately improve patient outcomes.

Prior to joining Sanofi, Dr. Nathwani was the Global Head of Medical Affairs, Novartis Pharma AG and served as a member of the Pharma Executive Committee, where he led the establishment of a Real-World Evidence Center of Excellence and Digital Medicine capability. Over his 11 years at Novartis, Dr. Nathwani held a number of senior development and commercial positions including the Global Head of the Critical Care Business Franchise and Senior Vice President, Global Development Head of the Cardiovascular and Metabolic Franchise.

Prior to joining Novartis, Dr. Nathwani held senior roles in R&D roles in GlaxoSmithKline, SmithKline Beecham, and Glaxo Group Research in both the UK and US. Dr. Nathwani graduated in medicine in London, specialized in cardiology and intensive care medicine, and holds a Master's in Business Administration.

Calum MacRae, MD, PhD, BSc

Member, Medical Strategic Advisory Board

Dr. MacRae is Vice-Chair for Scientific Innovation in the Department of Medicine at Brigham and Women’s Hospital (BWH), an Associate Professor of Medicine at Harvard Medical School, and an expert member of BWH’s Cardiovascular Genetics Program, which comprehensively evaluates, diagnoses and manages care for inherited cardiac disorder patients. In addition, he is a leading investigator at the BWH Genomics Center.

Dr. MacRae received his medical degree from the University of Edinburgh College of Medicine. He completed two internal medicine residency programs: one at Wellcome Trust Centre for Neuroimaging in London and the other at BWH. He then completed a fellowship in cardiovascular disease at Massachusetts General Hospital. Dr. MacRae is board certified in internal medicine and cardiovascular disease.

Dr. MacRae is a cardiologist and geneticist whose clinical interests include investigating new phenotypes and how research findings—including genomics discoveries—can be systematically implemented into clinical care. His research focuses on the biology and genomics of cardiovascular disease, specifically the biological basis of different arrhythmia susceptibilities. He holds five patents, has authored over 160 peer-reviewed publications and received research funding from the National Institutes of Health’s National Human Genome Research Institute.

Frank Rockhold, PhD, ScM, BA

Member, Medical Strategic Advisory Board

Dr. Rockhold is a Professor of Biostatistics and Bioinformatics at Duke University Medical Center (Scholars at Duke), Affiliate Professor of Biostatistics at Virginia Commonwealth University, and Managing Partner of HunterRockhold, Inc. His 40+-year career includes senior research positions at Lilly, Merck, and GlaxoSmithKline, where he retired as Chief Safety Officer and Senior Vice President of Global Clinical Safety and Pharmacovigilance. He has also held faculty appointments at six universities. Dr. Rockhold served for 9 years on the board of directors of the non-profit CDISC, most recently as Chairman, and is past president of the Society for Clinical Trials. He is a past member of the PCORI Clinical Trials Advisory Panel and is currently on the boards of the Frontier Science and Technology Research Foundation, Datavant, and an advisor to EMA.

Dr. Rockhold has diverse research interests and consulting experience in industry and academia including clinical trial design, data monitoring, benefit/risk, and most recently, safety and pharmacovigilance and has been a leader in the scientific community in promoting data disclosure and transparency in clinical research. Dr. Rockhold is widely published in major scientific journals across a wide variety of research topics.

Dr. Rockhold holds a BA in Statistics from The University of Connecticut, an ScM in Biostatistics from The Johns Hopkins University, and a PhD in Biostatistics from the Medical College of Virginia at Virginia Commonwealth University. Dr. Rockhold is an Elected Fellow of both the American Statistical Association and the Society for Clinical Trials, an Accredited Professional Statistician, PStat®, and a Chartered Statistician, CStat.

David Tovey, MD

Member, Medical Strategic Advisory Board

Dr. Tovey was the former Editor in Chief of The Cochrane Library for 10+ years. He was responsible for ensuring the quality and relevance of Cochrane Reviews and also for providing support for initiatives aimed at increasing their impact on clinical practice and health policy. He worked previously as Editorial Director for the BMJ Evidence Centre, which is the division of the BMJ Group that produces evidence-based resources for health professionals and the public. Dr. Tovey worked as a General Practitioner in an urban practice in South London for 15 years until 2003 and is a Fellow of the UK Royal College of General Practitioners.

Anthony Chang, MD, MBA, MPH, MS

Member, Medical Strategic Advisory Board

Dr. Chang attended Johns Hopkins University for his B.A. in molecular biology prior to entering Georgetown University School of Medicine for his M.D. He then completed his pediatric residency at Children’s Hospital National Medical Center and his pediatric cardiology fellowship at the Children’s Hospital of Philadelphia. From there, he accepted a position as attending cardiologist in the cardiovascular intensive care unit of Boston Children’s Hospital and as assistant professor at Harvard Medical School.

Dr. Chang has been the medical director of several pediatric cardiac intensive care programs and has served as the medical director of the Heart Institute at Children’s Hospital of Orange County. He is currently the Chief Intelligence and Innovation Officer (CIIO) and Medical Director of the Heart Failure Program at Children’s Hospital of Orange County. He has also been named a Physician of Excellence by the Orange County Medical Association and Top Cardiologist, Top Doctor for many years as well as one of the nation’s Top Innovators in Healthcare.

Dr. Chang has completed a Masters in Business Administration (MBA) in Health Care Administration at the University of Miami School of Business and graduated with the McCaw Award of Academic Excellence. He also completed a Masters in Public Health (MPH) in Health Care Policy at the Jonathan Fielding School of Public Health of the University of California, Los Angeles. Finally, he graduated with his Masters of Science (MS) in Biomedical Data Science with a subarea focus in artificial intelligence from Stanford School of Medicine and has completed a certification on artificial Intelligence from MIT.

Dr. Chang is known for several innovations in pediatric cardiac care, including introducing the cardiac drug milrinone and co-designing an axial-type ventricular assist device in children. He is a committee member of the National Institute of Health pediatric grant review committee. He is the editor of several textbooks in pediatric cardiology, including Pediatric Cardiac Intensive Care, Heart Failure in Children and Young Adults, and Pediatric Cardiology Board Review. He is the founder of the Pediatric Cardiac Intensive Care Society (PCICS) that launched the multi-disciplinary focus on cardiac intensive care for children. He is also the founder of the Asia- Pacific Pediatric Cardiac Society (APPCS) as well as the founder of three startup companies in artificial intelligence in medicine including: CardioGenomic Intelligence (CGI), LLC, Artificial Intelligence in Medicine (AIMed), LLC, and Medical Intelligence 10 (MI10), LLC.